IDIOPATHIC PULMONARY FIBROSIS (IPF)
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS (IPF) explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS (IPF) trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill tested to slow scarring lung disease
Disease control CompletedThis study tested a new oral medicine called INS018_055 in adults with idiopathic pulmonary fibrosis (IPF), a serious lung scarring disease. For 12 weeks, researchers compared the drug to a placebo pill in 71 participants to see if it was safe and if it could help slow the declin…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Simple arm test may help track lung disease impact
Knowledge-focused CompletedThis study aimed to understand how a 6-minute arm movement test relates to other measures of physical ability, fatigue, daily activities, and quality of life in people with idiopathic pulmonary fibrosis (IPF). Researchers tested 21 patients with stable IPF, having them perform se…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:40 UTC
-
Muscle wasting linked to worse outcomes in scarred lungs
Knowledge-focused CompletedThis study aimed to understand how common muscle loss (sarcopenia) is in people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Researchers measured muscle strength, lung function, walking ability, and quality of life in 60 patients to see if sarcopenia…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Mersin University • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:17 UTC